Major Market Shift in Influenza Treatment Industry: Companies Expand Influenza Treatment Options With Single-Dose Oral Medicines

What Is the Forecasted Market Size and Growth Rate for the Influenza Treatment Market?
In recent times, the scope of the influenza treatment market has been expanding consistently. The market, valued at $6.6 billion in 2024, is forecasted to escalate to $6.9 billion in 2025 with a compound annual growth rate (CAGR) of 4.5%. The growth observed during the historical period can be tied back to a surge in annual influenza cases, augmented government support for influenza studies and readiness programs, public education initiatives advocating for vaccination, the inception of comprehensive global influenza monitoring systems, and the expansion in healthcare facilities.

In the coming years, the influenza treatment market is projected to exhibit steady growth. By 2029, it is expected to surge to $8.16 billion, with a compound annual growth rate (CAGR) of 4.3%. This growth during the projected period could be attributed to the advent of novel antiviral drugs and treatment methods, wider immunization programs, ongoing enhancement and growth of healthcare facility, a surge in the elderly population, and the invention of new treatments. Key trends during the forecast period encompass moves towards the formation of universal vaccines, creativity in vaccine delivery mechanisms, assimilation of AI and big data, progress in personalized healthcare, and boosted partnerships among pharmaceutical corporations.

What Are the Main Catalysts for Growth in the Influenza Treatment Market?
The rise in communicable respiratory diseases is predicted to accelerate the influenza treatment market's growth in the future. Communicable respiratory diseases refer to infectious illnesses such as influenza, measles, or Respiratory Syncytial Virus (RSV) infections, which spread through physical contact with an infected person, exposure to their bodily fluids, or contact with contaminated items or surfaces. Driving factors for the expansion of communicable respiratory diseases involve larger population densities, lack of robust healthcare infrastructure, antibiotic misuse, and ease of international travel. The influenza treatment comprises antiviral medications and vaccines used to address various communicable respiratory diseases like flu, COVID-19, and other respiratory viruses. For example, the US-based national public health agency, the Centers for Disease Control and Prevention (CDC), reported in September 2023 that hospitalizations connected to RSV (Respiratory Syncytial Virus) jumped from 2 hospitalizations per 100,000 individuals for the week ending August 5, 2023, to 7 hospitalizations per 100,000 people by the week ending August 19, 2023. Hence, the escalated prevalence of communicable respiratory illnesses is fueling the influenza treatment market's expansion.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15832&type=smp

Which Businesses Are at the Forefront of Influenza Treatment Market Development?
Major companies operating in the influenza treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Fujifilm Holdings Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin Limited, NATCO Pharma Limited, BioCryst Pharmaceuticals Inc., NanoViricides Inc.

What Are the Latest Innovations in the Influenza Treatment Market?
Leading firms in the influenza treatment market are concentrating their efforts on growing their product range with innovative solutions such as single-dose oral medicines. These are created to treat flu in one oral dose and aim to increase patient adherence, improve treatment results, and obtain a greater market share. For example, Genentech Inc., a biotechnology company from the US, received approval from the U.S. Food and Drug Administration (FDA) for Xofluza (Baloxavir Marboxil) in August 2022. Xofluza is the initial and sole single-dose oral medicine providing an efficient and practical approach for handling acute uncomplicated influenza in children aged five to less than 12 years who have shown symptoms for not more than 48 hours, as well as other respiratory viruses.

How Is the Influenza Treatment Market Segmented?
The influenza treatment market covered in this report is segmented -

1) By Product Type: Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, Other Products
2) By Route Of Administration: Oral, Other Routes Of Administration
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Other Distribution Channels

Subsegments:
1) By Peramivir: Intravenous Peramivir, Peramivir Injection
2) By Zanamivir: Inhaled Zanamivir, Zanamivir Diskhaler
3) By Oseltamivir Phosphate: Oseltamivir Capsules, Oseltamivir Oral Suspension
4) By Baloxavir Marboxil: Baloxavir Tablets, Baloxavir Granules For Oral Suspension
5) Other Products: Rimantadine, Amantadine

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/influenza-treatment-global-market-report

Where Is the Influenza Treatment Market Growth Most Prominent?
North America was the largest region in the influenza treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the influenza treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Influenza Treatment Global Market Report?

- Market Size Analysis: Analyze the Influenza Treatment Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Influenza Treatment Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Influenza Treatment Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Influenza Treatment Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15832

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.